Revance Releases Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aegis Capital Reiterates Buy on Revance Therapeutics (RVNC) Following 4Q Report
February 28, 2017 8:18 AM ESTAegis Capital reiterated a Buy rating and $28.00 price target on Revance Therapeutic (NASDAQ: RVNC) following the company's 4Q earnings report. Revance reiterated its prior guidance for cash burn of $102 to $112 mil for 2017.
Analyst Difei Yang commented, "Yesterday, Revance Therapeutics announced fourth quarter... More
Revance Therapeutics (RVNC) Misses Q4 EPS by 11c
February 27, 2017 4:14 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.95), $0.11 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.
2017 Financial Outlook
Revance reiterates its financial guidance provided in January 2017. Revance expects cash... More
